5 Key Takeaways

• 1

  Presbyopia drops, such as Vuity and Qlosi, offer a non-invasive alternative for managing near vision in patients over 40.

• 2

  Clinical trials demonstrated that presbyopia drops significantly improve near vision while preserving distance vision, even in low-light conditions.

• 3

  Careful patient selection and education are crucial for optimal outcomes, particularly for motivated individuals aged 40 to 50 with early to moderate presbyopia.

• 4

  The FDA approved a twice-daily dosing option for Vuity in 2023, extending its effectiveness from 6 to 9 hours.

• 5

  Common side effects of presbyopia drops include headaches and eye irritation, emphasizing the importance of patient counseling and adherence.